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Cancer researchers will now know
how funding in Britain follows
public perceptions following the
first analysis of priorities across a
range of funding bodies. They will
be looking at why investigators
working with lung cancer research
receive just 3 per cent of British
funding into causes of individual
cancers and their treatment when
it accounts for 35,000 deaths a
year, more than one fifth of all
cancer deaths.
Sir Paul Nurse, director of
Cancer Research UK said: ‘We
could almost eliminate lung
cancer in this country because we
know the primary cause is
tobacco. The problem has almost
moved from it being a research
problem to being a public health
problem.’
One of the problems facing
researchers is that lung cancer
patients are more ill by the time
they are diagnosed than many
other patients. But there has been
substantial progress in fighting the
disease, at least in men from the
higher social classes, since
scientists first established the link
with tobacco smoke. However,
deaths among women are still
rising.
In contrast breast cancer gets a
relatively high proportion of
funding compared with its actual
incidence. Although numbers of
patients with the disease are
rising, survival rates are also
improving.
Leukaemia, an area where
Britain is a world leader in
research, also enjoys high levels
of financial support. Cancer of the
blood is easier to study and its
high incidence among children
helps to create a high emotional
attachment to members of the
public.
The funding discrepancy is
highlighted in an analysis of
research funding by the National
News focus
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A new database will make Britain’s substantial but diverse spending on
cancer research more accessible to both local researchers and the
international research community facilitating strategic planning for the
future. Nigel Williams reports.
Rich pickings: New studies across 15 major UK cancer funding bodies reveal that money often follows the diseases highest in public
profile. Whereas lung cancer receives just a small amount of cash, leukaemia, which affects children more than many other cancers,
received a high level of funding. (Picture: Science Photo Library.)
Cancer Research Institute (NCRI),
a partnership of 15 main research
funders.
The NCRI was established in
April last year with the aim of
accelerating progress in cancer
research in the UK for the benefit
of cancer patients. This initiative
was stimulated by a new way of
thinking within the cancer
research community and a desire
for greater coherence and more
efficiency.
‘The central aim of the NCRI is
to add value by providing an
independent forum to facilitate
joint strategic planning and
develop national resources that
are of benefit to the whole UK
cancer research community,’ the
report says.
The report presents an analysis
of the direct spend component of
cancer research (£257 million per
year) funded by these fifteen
leading cancer research
organisations.
‘In the past, strategic planning
of cancer research on a national
level has not been possible
because of a lack of reliable and
comparable data on the current
activities of the major research
funders,’ the report says. In order
to overcome these issues the
NCRI has established the Cancer
Research Database (CRD) which
is designed to contain accurate
information on the directly
supported cancer research
currently being funded by NCRI
members.
Information on the CRD is in
the form of a common data-set
that includes principal
investigator(s), an abstract of the
research being conducted and
details of funding awarded. In
order to interrogate the database
in a meaningful and reproducible
way, every research project has
been coded using three
internationally recognised
classification systems: the
Common Scientific Outline (CSO)
– a classification system of
cancer-related research
terminology that categorises
research activity into specific
areas (for example, biology,
aetiology, treatment etc.);
disease site codes; and Medical
Subheadings (MeSH). The use of
these standardised coding
systems will, for the first time,
allow reliable comparisons
between portfolios of national
and international cancer
research.
The largest proportion of the
NCRI members’ spend is in the
field of biological research, with
most organisations funding
research in this area. Research on
aetiology and treatment are also
well supported by members. Two
areas where research investment
across the majority of funders
appears to be relatively low are
prevention research, and cancer
control, survival and outcomes
research.
Two key areas have been
highlighted in the first analysis of
the CRD that member
organisations have agreed would
benefit from much closer joint
strategic examination: research
into cancer risk and prevention
and research into supportive and
palliative care. ‘These are both
cross-cutting areas of research
that are important to all cancer
types and encompass all NCRI
organisations,’ the report says.
They both involve a significant
patient-based focus and are
characterised by being areas of
low direct research activity, it
argues.
There are a large number of
different organisations funding
cancer research in the UK.
Previously these organisations
have collaborated with one
another but never before have
they come together in a single
body to map out what they are
doing collectively and jointly plan
for the future. Over the past few
years there has been much
debate about cancer research in
the UK and many individual
organisations have been asking
the same question, the report
says: ‘Are we being as effective as
we could be?’
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Biology bulge: New figures on the destination of funds for cancer research across 15 major sponsors in the UK, from government to
private charities, reveals a focus on generic biological research and much less on more specific areas where new opportunities are
now perceived to exist for future research funding.
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